Form 4: Exelixis Director Maria C. Freire Granted 9,812 Restricted Stock Units

Exelixis, Inc. Director Maria C. Freire was granted 9,812 restricted stock units (RSUs) on May 29, 2025, as part of the company's equity incentive plan.

Summary

• Maria C. Freire, a Director of Exelixis, Inc. (EXEL), acquired 9,812 shares of Common Stock in the form of Restricted Stock Units (RSUs) on May 29, 2025.
• These RSUs were granted at a price of $0 per unit, consistent with equity incentive plan awards.
• Following this transaction, Maria C. Freire beneficially owns a total of 100,819 shares of Exelixis Common Stock.
• The 9,812 RSUs will vest 100% on May 29, 2026, contingent upon her continuous service to the company.
• The total beneficial ownership includes 28,650 shares of Common Stock that will be issued upon the vesting of RSUs.

Sentiment

Score: 7

Explanation: The filing is a standard disclosure of an equity grant to a director, which is generally a positive sign of aligning interests, but it does not contain significant new operational or financial news to warrant a higher score. It's a neutral-to-slightly positive administrative update.

Positives

• The grant of restricted stock units aligns the director's interests with long-term shareholder value.
• The equity incentive plan encourages retention and performance of key personnel.

Risks

• Vesting of the 9,812 RSUs is subject to continuous service, meaning the director must remain with the company until May 29, 2026, to receive the shares.

Future Outlook

The vesting schedule for the granted RSUs indicates a future issuance of shares on May 29, 2026, contingent on the director's continued service.

Industry Context

This transaction is a routine insider compensation disclosure, common across all industries, particularly in biotechnology where equity incentives are a standard component of executive and director compensation to align interests with long-term company performance.

Comparison to Industry Standards

• The grant of restricted stock units to a director is a standard practice in corporate governance and executive compensation across various industries, including biotechnology.
• Companies like Amgen, Gilead Sciences, and Biogen frequently utilize similar equity incentive plans to compensate and retain their board members and executives, aligning their interests with shareholder value.
• The specific number of units granted would typically be benchmarked against peer companies of similar market capitalization and stage of development, though this filing does not provide such comparative data.

Corporate Governance

Stakeholder Impact

• Shareholders: Interests are aligned with the director through equity ownership, potentially encouraging long-term strategic decisions.
• Employees: No direct impact mentioned, but part of a broader equity incentive framework.

Next Steps

• Continued service of Maria C. Freire until May 29, 2026, for the RSUs to vest.
• Issuance of 9,812 shares of Common Stock to Maria C. Freire upon vesting on May 29, 2026.

Key Dates

Keywords

Exelixis, EXEL, Form 4, Restricted Stock Units, RSUs, Equity Incentive Plan, Director Compensation, Insider Transaction, Maria C. Freire